Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Emerald Health Biotechnology

Emerald Health Biotechnology
2003 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of pharmaceutical drugs created to focus on new non-psychotropic cannabinoids for the treatment of inflammatory and neurodegenerative diseases. The company's operations include development of cannabidiol and cannabigerol chemical derivatives that improve the therapeutic properties of the natural hit compounds which addresses unmet clinical need in the treatment of multiple sclerosis, Huntington's disease and scleroderma.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Emerald Health Research
Primary Office
  • Parque Científico Tecnológico de Córdoba (Rabanales 21)
  • Calle Astrónoma Cecilia Payne, Edificio Centauro, Planta 1
  • 14014 Córdoba
  • Spain

Emerald Health Biotechnology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Emerald Health Biotechnology‘s full profile, request access.

Request full access to PitchBook

Emerald Health Biotechnology Executive Team (7)

Name Title Board
Seat
Contact
Info
Mari Luz Bellido Ph.D Managing Director & Chief Executive Officer
María del Pilar Díaz Espejo-Saavedra Chief Financial Officer
Bernd Fiebich Co-Founder
Giovanni Appendino Co-Founder
Michael Heinrich Co-Founder
You’re viewing 5 of 7 executives. Get the full list »